STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Category: Pharmalot
STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug
As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group…
STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharmalittle: FDA flags safety concerns with CRISPR-based sickle cell treatment; FDA warns about eye drop infection risk
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Eisai reports injectable version of Alzheimer’s drug as effective as IV; Pfizer says combo flu and Covid shot shows strong response
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
.jpg)
STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies,…
STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee
Novartis has gone to court to gain access to Takeda Pharmaceutical documents over concerns that…
STAT+: Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short
Earlier this month, the U.K. government issued a proposal to gather information and opinions about…
STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro
As demand for weight-loss treatments intensifies, Eli Lilly has filed a complaint with the U.S….
STAT+: Pharmalittle: Pfizer prices Paxlovid at $1,400 for a five-day course; EMA warns of counterfeit Ozempic
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: People with obesity harmed by exclusion from studies; Teva sues Colorado over ‘unconstitutional’ program
Rise and shine, everyone, another busy day is on the way. We can tell, in…
STAT+: Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors
In the latest tussle over the cost of medicines, Teva Pharmaceuticals has filed a lawsuit…
STAT+: Pharmalittle: Rite Aid files for bankruptcy; Alzheimer’s brain scans get broader Medicare coverage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Eye docs urge Medicare to lower insurance hurdles amid shortage of repackaged Avastin
Due to a shortage of a widely used compounded medicine for serious eye diseases, two…
STAT+: Pharmalittle: Makers of toxic cough syrups face new actions; Cassava suffers new blow over Alzheimer’s drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail
Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to…
STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer
A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine…
STAT+: Medicare may plan to negotiate drug prices, but some states are taking their own steps to lower costs
Anticipation may be high that Medicare can wring lower prices out of drugmakers, but a…
STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024
Hello, everyone, and nice to see you again. We have returned from an extended weekend…
STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy
In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound…
STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases
Several cases of sepsis — three of which ended in patients deaths — were traced…
STAT+: Pharmalittle: FDA finds ‘potential systemic bias’ in Amgen cancer drug trial; drugmakers organize to push back on antitrust reviews
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
In the latest battle over access to medicines, Colombian authorities have decided to issue a…
STAT+: Pharmalittle: Drugmakers agree to negotiate Medicare prices under protest; AstraZeneca settles lawsuits over heartburn drugs
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: Court strikes down Trump-era rule that allowed health insurers to broadly use copay accumulators
A U.S. judge has struck down a Trump administration rule that allowed health insurers not…
STAT+: Pharmalittle: Court allows Medicare drug price negotiation to proceed; J&J will not enforce patents on key TB drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: J&J agrees not to enforce patents on a key tuberculosis drug in dozens of poor countries
In an unexpected turnabout, Johnson & Johnson announced it would not enforce any of its…
STAT+: Unitaid slams J&J over pricing and patents for a tuberculosis drug
In a highly unusual move, Unitaid has publicly criticized Johnson & Johnson over its pricing…
STAT+: Generic makers fall short when providing access to low- and middle-income countries, analysis finds
A handful of the largest purveyors of generic medicines have made only halting progress to…
STAT+: Sales from controversial drug discount program rose to $54 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $53.7…
STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments
Ophthalmologists who accepted payments from drug companies were less likely to prescribe a cheaper medicine…
STAT+: Pharmalittle: FDA advisers vote overwhelmingly against ALS treatment; weight-loss drugs scrutinized over reports of suicidal thoughts
Top of the morning to you, and a fine one it is. Despite overcast skies,…
STAT+: Pharmalittle: Pharma would lose loyal ally if Menendez leaves Senate; EMA to discuss anesthesia risk for weight-loss drugs
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: FDA to furlough one-fifth of staff if government shuts down; FDA cites ‘grossly deficient’ data for ALS drug
Hello, everyone, and nice to see you again after we engaged in an extended respite….
STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, writing to…
STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny
Hello, everyone, and how are you this fine, sunny morning? We are doing just fine,…
STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions
For the fourth time this year, Novartis has been reprimanded by a U.K. trade group…
STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro
As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding…